Background: Effective treatment options are limited for advanced nonsmall cell lung cancer (NSCLC) patients who progressed after first-line therapy. Pronounced efficacy of anti-programmed cell death protein 1 (anti-PD-1) combination strategy was observed in first-line setting, therefore we assessed whether the addition of chemotherapy and/or bevacizumab to anti-PD-1 could improve clinical outcomes in secondline or later advanced NSCLC. Method: Advanced NSCLC patients treated with anti-PD-1 therapy from March 2015 to July 2017 were retrospectively screened for eligibility. First-line treatment or combined drugs beyond chemotherapy or bevacizumab were excluded. The primary objective was progression-free survival (PFS). Secondary objectives were overall response rate (ORR), disease control rate (DCR) and safety. Results: 55 patients were included in the analysis (monotherapy, n¼33; combination therapy, n¼22). 90.0% of the patients have progressed after standard platinum-based chemotherapy in previous line therapies. Combination group exhibited longer PFS than monotherapy group (median, 7.5 vs 3.3 months, adjusted HR 0.32[0.16-0.65], P ¼0.001). 31.8% (7/22) patients in combination group achieved an objective response compared with 10.0% (3/30) in monotherapy group (P ¼ 0.075). The DCR was 95.5% (21/22) in combination group compared with 46.7% (14/30) in monotherapy group (P<0.001). Adverse events of grade 3 or worse were occurred in 22.7% of the patients in the combination group and in 6.1% of those in monotherapy group. Most of the adverse events were manageable. Conclusion: Combination of anti-PD-1 plus chemotherapy and/or bevacizumab could be an effective and tolerable therapy as second-line or later treatment option for advanced NSCLC patients. Keywords: non-small cell cancer, immune checkpoint inhibitor, combination The First Affiliated Hospital of Guangzhou Medical University were analyzed retrospectively, including age, sex, smoking history, clinical symptoms, pathological type, classification, lung function and treatment. The patients were divided into COPD treatment group and control group according to whether the patients received treatment for COPD. Then compare the therapeutic effect of the two groups. Results: There were no significant differences in the disease control rate(DCR) and objective response rate (ORR) of COPD treatment group with control group (p＞0.05),while the period of first-line chemotherapy treatments in COPD treatment group were more than that of control group (4.8vs.3.8,p<0.05), and patients in COPD treatment group are more likely to receive second-line treatment (95.7%vs.75.0%,p<0.05). Progression-free surival (PFS) of COPD treatment group were significantly higher than control group(6.0 months vs.3.5 months, p<0.05),and Overall survival(OS) of COPD treatment group were significantly higher than control group(18.0 months vs.6.0 months,p<0.05). Conclusion: 1. COPD combined with advanced NSCLC occurs in male smokers more. The performance status (PS) score of majority range from 1 to 3. 2. There were no significant differences in the short-term therapeutic effect of two group, while the period of firstline chemotherapy treatments, OS and PFS of patients which regularly receive anti-COPD therapy were significantly higher than control group. 3. Patients in regular COPD treatment group are more likely to receive second-line chemotherapy. Keywords: simultaneous treatment of cancer and lung itself, advanced non-small cell lung cancer, chronic obstructive pulmonary disease
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